Skip to main content

2023 IKCS: Europe Main banner

Tweets by 2023 IKCS: Europe

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Title

Browse by Poster Title

Type here to filter the list

6
2022 Global Patient Survey: Reported Experience of Diagnosis, Management, and Burden of Renal Cell Carcinomas
Other

Favorite
7
Circulating B cells subpopulations and outcomes to Checkpoint Blockade in patients with renal cell carcinoma.
Basic Science

Favorite
8
Understand the Biology of Kidney Cancer Progression
Basic Science

Favorite
9
Characterisation of HIF-mediated genoprotection in clear cell renal cell carcinoma
Basic Science

Favorite
10
The use of Renal tumor biopsies (RBx) has increased at Haukeland University Hospital(HUS) during 2008-2022
Diagnostics

Favorite
11
Correlation of PSMA expression on [18F]PSMA-1007 PET with morphological changes in patients with metastatic renal cell cancer undergoing tyrosine kinase and checkpoint inhibitor therapy
Imaging

Favorite
12
T-Rex Study: Real-world evidence and patient-reported outcomes of mRCC patients treated first-line with tivozanib
Patient-reported Outcomes

Favorite
13
Active Surveillance for Small Renal Masses: Living with an potential untreated cancer
Patient-reported Outcomes

Favorite
14
Exploring the perspectives of patients with localised kidney cancer on their treatment decisions: a qualitative study
Patient-reported Outcomes

Favorite
15
Patient experience of follow-up after surgery for kidney cancer: a focus group study
Quality of Care and Quality Improvement

Favorite
16
Clinical Outcome of Patients with Primary Metastatic Renal Cell Carcinoma Carefully Selected for Cytoreductive Nephrectomy: A Nationwide Real-World Data
Real-World Evidence

Favorite
17
Patient characteristics, treatment patterns and outcomes for patients with renal cell carcinoma (RCC) in England
Real-World Evidence

Favorite
18
Optimal Duration of Frontline Immunotherapy in Patients with Metastatic Renal Cell Carcinoma (mRCC)
Real-World Evidence

Favorite
19
Real World Experience (RWE) of Ipilimumab and Nivolumab compared to Pembrolizumab and Axitinib in Advanced Renal Cell Carcinoma (RCC)
Real-World Evidence

Favorite
20
A UK real-world observational study of avelumab + axitinib (A+Ax) in advanced renal cell carcinoma (RCC): exploratory analysis of 24-month interim results in patients with non-clear cell histology
Real-World Evidence

Favorite
21
Real-world recurrence patterns in Danish renal cell carcinoma patients
Real-World Evidence

Favorite
22
Baseline characteristics from the real-world CARINA study of patients with advanced renal cell carcinoma treated with cabozantinib after first-line checkpoint inhibitor-based combination therapy
Real-World Evidence

Favorite
23
Role of cytoreductive nephrectomy in metastatic RCC, single institution experience
Real-World Evidence

Favorite
24
Real-world outcomes of nivolumab (NIVO) + ipilimumab (IPI) in patients with previously untreated clear cell advanced renal cell carcinoma (aRCC) in France.
Real-World Evidence

Favorite
25
4-weekly avelumab administration plus axitinib in patients with metastatic renal cell carcinoma: A single centre analysis of patient outcomes
Real-World Evidence

Favorite
26
Anticoagulant treatment and thromboembolic events prior to diagnosis of renal cell carcinoma: Impact on stage distribution
Real-World Evidence

Favorite
27
Immune-related adverse events after ≥12 months of immune checkpoint inhibitor therapy in metastatic renal cell carcinoma
Treatment Toxicities and Symptom Management

Favorite
28
Real world experience of managing immunotherapy toxicity at a UK tertiary centre
Treatment Toxicities and Symptom Management

Favorite
29
Efficacity and safety of cabozantinib rechallenge in metastatic renal cell carcinoma: a retrospective multicentric study
Therapeutics- Systemic (Ablation, Interventional Radiology, Medical Oncology, Radiation Therapy, Surgery, Urology)

Favorite
30
Association of ABO blood type with toxicity and response to immunotherapy in metastatic renal cell carcinoma (mRCC)
Therapeutics- Systemic (Ablation, Interventional Radiology, Medical Oncology, Radiation Therapy, Surgery, Urology)

Favorite
31
Efficacy of immune checkpoint inhibitor (ICI) combination therapy as first-line (1L) treatment in metastatic renal cell carcinoma (mRCC).
Therapeutics- Systemic (Ablation, Interventional Radiology, Medical Oncology, Radiation Therapy, Surgery, Urology)

Favorite
32
Clinical benefit of cabozantinib in patients with advanced renal cell carcinoma (aRCC) after checkpoint inhibitor (CPI) therapy: interim results from the Phase 2 CaboPoint trial
Therapeutics- Local (Primary and Metastases)

Favorite
33
Investigating response to Axitinib in Kidney Cancer with Venous Tumour Thrombus: translational analysis of the NAXIVA Trial
Tumor Biology, Biomarkers, and Pathology

Favorite
34
Baseline cytokine levels according to IMDC score in patients with metastatic clear cell renal cell carcinoma treated with nivolumab in the NIVOREN GETUG-AFU 26 Translational study
Tumor Biology, Biomarkers, and Pathology

Favorite
35
Renal cell carcinoma and therapeutic opportunities in the paradigm shift – a case report
Survivorship

Favorite
36
Long survivorship in metastatic kidney cancer during targeted-therapy era
Survivorship

Favorite
37
The metanephric adenoma - a benign variant of the Wilms' tumor: case report of an extremely rare kidney tumor
Tumor Biology, Biomarkers, and Pathology

Favorite
38
REFINE (REduced Frequency ImmuNE checkpoint inhibition in cancers): a multi-arm phase II trial testing reduced intensity immunotherapy across different cancers
Other

Favorite